Braxia Scientific

Braxia Scientific is a research-driven medical solutions company aimed at reducing the disease burden of brain-related mental illnesses such as major depressive disorder. The company leverages its intellectual property development platform to develop psychedelic products like ketamine and psilocybin derivatives. Braxia Scientific operates multidisciplinary community clinics in Mississauga, Toronto, Ottawa, and Montreal through its wholly-owned subsidiary, Canadian Rapid Treatment Center of Excellence Inc., providing rapid treatment for patients with depression.On May 17, 2021, its stock trading symbol on the OTC Market changed from SHRMF to BRAXF.